Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Further analysis of the Phase 2b ADVANCE study reinforces Phase 2b EXPAND results and ...

7 September 2026 · By · Wire by Fusion42

Published

7 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at tradingview.com →

◆ Verified

Fusion42 · 7 September 2026 · Fusion42 review

SynAct Pharma's post-hoc analysis of the Phase 2b ADVANCE study confirms results from the earlier Phase 2b EXPAND study on resomelagon for rheumatoid arthritis, supporting advancement to Phase 3 trials with planned FDA discussions in Q4 2026 on trial design.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You have a clearer regulatory pathway for resomelagon as FDA talks on Phase 3 trial design open a chance to shape pivotal study parameters; align your early RA treatment strategies to leverage stable inflammation baselines in trials.

◆ Coverage

1 source · 7 Sep 2026

◆ Related on Wire

◆ Topics

Biotechclinical-trialrheumatoid-arthritisfda-engagementbiotechdrug-development